Increasing evidence for omalizumab in the treatment of bullous pemphigoid

Affiliations

¹ Department of Medicine, Division of Dermatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
² David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.

Case Reports

Sarah Lonowski et al. JAAD Case Rep. 2020.

. 2020 Feb 26;6(3):228-233.

doi: 10.1016/j.jdcr.2020.01.002. eCollection 2020 Mar.

¹ Department of Medicine, Division of Dermatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
² David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.

No abstract available

Keywords: BP, Bullous pemphigoid; DIF, Direct immunofluorescence; IgE; autoimmune skin disease; bullous pemphigoid; omalizumab; steroid sparing.

References

1. Fania L., Caldarola G., Müller R. IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses. Clin Immunol. 2012;143(3):236–245. - PubMed
1. Messingham K.A., Holahan H.M., Fairley J.A. Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid. Immunol Res. 2014;59(1-3):273–278. - PubMed
1. Fairley J.A., Baum C.L., Brandt D.S., Messingham K.A. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol. 2009;123(3):704–705. - PMC - PubMed
1. Yu K.K., Crew A.B., Messingham K.A.M., Fairley J.A., Woodley D.T. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol. 2014;71(3):468–474. - PMC - PubMed